Colpron Francoise 4

What Happened
Francoise Colpron, a director of Celestica Inc. (CLS), received equity awards classified as derivative grants: 115 restricted share units (RSUs) on May 19, 2026 and 869 director‑RSUs (D‑RSUs) on May 20, 2026, for a total of 984 units. The Form 4 reports an acquisition price of $0.00 for each grant (standard for contingent RSU awards on Form 4); these are awards, not open‑market purchases or sales.

Key Details

• Transaction types/dates: A (Award/Grant) — 115 RSUs on 2026‑05‑19; 869 D‑RSUs on 2026‑05‑20. Price per unit reported: $0.00.
• Vesting: the 115 RSUs vest 1/3 annually over three years (anniversaries of May 19, 2026); the 869 D‑RSUs vest in full on the first anniversary (May 20, 2027).
• What the awards mean: each RSU/D‑RSU is a contingent right to receive one common share (or, in some cases, cash in lieu) upon settlement. D‑RSUs may be subject to the holder’s deferral election.
• Shares owned after transaction: not disclosed in the provided Form 4.
• Filing timeliness/other notes: Form 4 was filed May 20, 2026 (covers transactions of May 19–20) — no late‑filing indication in the provided document. The filing does not indicate a 10b5‑1 plan or tax‑withholding settlement at grant.

Context
RSU and D‑RSU grants are standard director compensation and are different from open‑market purchases (which can be interpreted more directly as a bullish signal). Because these are contingent awards that vest in the future and can be settled in shares or cash, they do not represent immediate share purchases or sales.